Remicade Superior in Endoscopic Remission vs. Entyvio for UC
For UC patients naïve to biologics, Remicade (infliximab) was shown to be superior in corticosteroid-free clinical remission, as well as endoscopic remission versus Entyvio (vedolizumab). This recent analysis found that clinical remission percentages were close at year one, with Remicade at 39.9% and Entyvio at 38.6%. Both of these are viable biologic options for the … Read more